Document Detail


Exposure-response relationships for oxaliplatin-treated colon cancer cells.
MedLine Citation:
PMID:  18043128     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Data are lacking for an optimal infusion length for oxaliplatin administered intraperitoneally. Our objectives were to establish the roles of hyperthermia and an effective length of oxaliplatin treatment in maximizing antitumor activity. SW620 cells were treated for 0.5 vs. 2 h and at 37 vs. 42 degrees C. Cytotoxicity, cell cycle analysis, subG1 and survival were assessed with the MTT assay, flow cytometry and the clonogenic assay. The IC50 for cells treated at 37 degrees C was 2.90+/-0.83 microg/ml and at 42 degrees C, 1.99+/-0.66 microg/ml (P=0.14). The Emax for 37 degrees C was 93.9+/-2.57% and for 42 degrees C, 97.8+/-1.59% (P=0.05). The subG1 fraction did not differ between cells treated at 37 and 42 degrees C (P=0.12). The IC50 for the cells treated for 0.5 h was 10.6+/-0.60 microg/ml and for 2 h, 2.80+/-1.70 microg/ml (P=0.02). The Emax for 0.5 h was 87.9+/-5.13% and for 2 h, 96.6+/-3.35% (P=0.09). SubG1 for 0.5 h was 8.24+/-1.33% and for 2 h, 15.8+/-2.45% (P=0.02). Clonogenic assays demonstrated diminished survival when treated with low concentrations (10 microg/ml) of oxaliplatin combined with heat treatment (P=0.017) for 2 h, but not 0.5 h. Similar clonogenic assay experiments were performed with the oxaliplatin-resistant WiDr cell line, and differences in survival following oxaliplatin and heat treatment were again observed for 2 h, but not for 0.5 h (P=0.002). Drug treatment for 2 h of both SW620 and WiDr cell lines is superior to treatment for 0.5 h. Cell kill effects are reliant on treatment length; hence, the choice of time exposure must be made with a view to maintaining a balance between the cell kill effects and the clinical feasibility of treating the patient.
Authors:
Mark N Kirstein; Stephanie A Root; Megan M Moore; Katie M Wieman; Brent W Williams; Pamala A Jacobson; Paul H Marker; Todd M Tuttle
Related Documents :
20508518 - Valproic acid inhibits proliferation of human coronary vascular cells (si/mpl-ratio: 0....
6234958 - The effect of tunicamycin on leishmania braziliensis cell growth, cell morphology and u...
11341958 - 1h nmr-visible mobile lipid domains correlate with cytoplasmic lipid bodies in apoptoti...
17216468 - Bioconversion of butyronitrile to butyramide using whole cells of rhodococcus rhodochro...
18670168 - (-)-epigallocatechin 3-o-gallate (egcg)-induced apoptosis in normal rat kidney intersti...
24353178 - Elevated mouse hepatic betatrophin expression does not increase human beta-cell replica...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  19     ISSN:  0959-4973     ISO Abbreviation:  Anticancer Drugs     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-11-28     Completed Date:  2008-01-23     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  37-44     Citation Subset:  IM    
Affiliation:
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA. kirst002@umn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Cell Cycle / drug effects
Cell Line, Tumor
Cell Survival / drug effects
Colonic Neoplasms / drug therapy*,  pathology
Dose-Response Relationship, Drug
Flow Cytometry
Hot Temperature
Humans
Organoplatinum Compounds / pharmacology*
Time Factors
Tumor Stem Cell Assay
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Organoplatinum Compounds; 63121-00-6/oxaliplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis and anticancer activities of 6-amino amonafide derivatives.
Next Document:  Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute mye...